DPP-4 INHIBITORS: TODAY AND TOMORROW. WHAT WE EXPECT FROM INCRETIN-STIMULATING THERAPY?


Cite item

Full Text

Abstract

Diabetes mellitus (DM) occupy the one of the leading places among the immediate causes of death along with cardiovascular and oncologic diseases; therefore, resolution of issues related to the problem of diabetes is delivered on the national level in many countries. Type 2 diabetes mellitus (DM2) is a heterogeneous disease, developing as a result of a combination of congenital and acquired factors. Algorithms of specialized medical care for DM patients (Issue 5, 2011, Moscow) include new approaches to drug therapy of DM2. Thus, the use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is recommended since the beginning of treatment and at all subsequent stages. This article presents materials of discussion held in the VIII Moscow City Congress of the Endocrinologists (13-14 March, 2012). The discussion addressed the following issues: how start of oral therapy of DM2 with DPP-4i and its intensification should be guided; what important additional effects DPP-4i have; what prospects DPP-4i have in the future?

References

  1. Dejager S. Vildagliptine in drug-naive patients with type 2 diabetes: 24 weeks, double blinde, randomized, placebo-controlled, multiple dose study. Horm Met Resp 2007:39:218-23.
  2. Schweizer A, et al. Diabet Med 2007;24:955-61. Göke B, et al. Horm Metab Res 2008;40:892-95.
  3. Stokes J, Kannel WB, Wolf, PA, Cupples LA, D Agostino RB. The relative importance of selected risk factors for various manifestations cardiovascular disease among men and women from 35 to 64 years old 30 years of follow-up in the Framingham Study. Circulation 1987;75:65-73.
  4. Wolf PA, D Agostino RB, Delanger AJ, Kannel WB. Probability of stroke a risk profile from the Framingham study. Stroke 1991;22:312-18.
  5. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes.Stroke1996;27:63-8.
  6. D'Alessio DA, et al. Contains patients on vildagliptin alone and those on vildagliptin plus metformin. J Clin Endocrinol Metab 2009;94:81-8.
  7. Bosi E, Dotta F, J Y, Goodman M, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009:1-10.
  8. Bosi, et al. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin. Diabetes care 2007;30(4):890-95.
  9. Matthews, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab2010;12:780-89.
  10. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11(8):804-12.
  11. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes II. Mortality results. Diabetes 1970;19:789-815.
  12. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10(11):1114-24.
  13. Fonseca V, et al. Diabetologia 2007;50:1148-55.
  14. Boschmann, et al. Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients. J Clin Endocrinol Metab 2009;94:846-52.
  15. Azuma, et al. Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes. J Clin Endocrinol Metab 2008;93:459-64.
  16. Ahren, et al. Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes care 2004;27(12):2874-80.
  17. Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993;265:374-81.
  18. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-19.
  19. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev 2007;87:1409-39.
  20. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:199-206.
  21. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001;50:785-96.
  22. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 2007;9:153-65.
  23. Fred F Ferri. Practical guide to the care of the medical patient. 6 ed. 2004. Br J Diabetes Vasc Dis 2006;6(5):207-15
  24. DeFronzo RA. Br J Diabetes Vasc Dis 2003;3(1):24-40.
  25. The Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care 2002;25(12):2165-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies